- Home
- ONL vs HLVX Comparison
ONL vs HLVX Comparison
Compare ONL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- HLVX
- Stock Information
- Founded
- ONL 2021
- HLVX 2020
- Country
- ONL United States
- HLVX United States
- Employees
- ONL N/A
- HLVX N/A
- Industry
- ONL Real Estate Investment Trusts
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- HLVX Health Care
- Exchange
- ONL Nasdaq
- HLVX Nasdaq
- Market Cap
- ONL 119.7M
- HLVX 105.2M
- IPO Year
- ONL N/A
- HLVX 2022
- Fundamental
- Price
- ONL $2.55
- HLVX $2.05
- Analyst Decision
- ONL Hold
- HLVX Hold
- Analyst Count
- ONL 1
- HLVX 1
- Target Price
- ONL N/A
- HLVX $2.00
- AVG Volume (30 Days)
- ONL 370.5K
- HLVX 504.5K
- Earning Date
- ONL 08-06-2025
- HLVX 08-11-2025
- Dividend Yield
- ONL 3.13%
- HLVX N/A
- EPS Growth
- ONL N/A
- HLVX N/A
- EPS
- ONL N/A
- HLVX N/A
- Revenue
- ONL $154,796,000.00
- HLVX N/A
- Revenue This Year
- ONL N/A
- HLVX N/A
- Revenue Next Year
- ONL N/A
- HLVX N/A
- P/E Ratio
- ONL N/A
- HLVX N/A
- Revenue Growth
- ONL N/A
- HLVX N/A
- 52 Week Low
- ONL $1.46
- HLVX $1.34
- 52 Week High
- ONL $4.39
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- ONL 54.98
- HLVX 48.11
- Support Level
- ONL $2.51
- HLVX $2.07
- Resistance Level
- ONL $2.72
- HLVX $2.16
- Average True Range (ATR)
- ONL 0.12
- HLVX 0.07
- MACD
- ONL -0.02
- HLVX -0.01
- Stochastic Oscillator
- ONL 37.14
- HLVX 29.41
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.